TARAProtara TherapeuticsSigning up patients
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
Bladder (Urothelial, Transitional Cell) Cancer · Non-Muscle Invasive Bladder Carcinoma · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +3.3
A key executive is leaving
Since Jun 29, 2026 · was worth 15, fading over time
Worry score3
Score over time
- Stage
- Phase 3
- Patients
- 284 (planned)
- Started
- May 29, 2026
- Main results expected
- Apr 2028
- Fully finished
- Nov 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of high-grade complete response
Measured over: Month 6
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 3.3, since 2026-06-29, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT07480356 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC